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Abstract
Converging evidence from genetic, pathological and experimental studies have increasingly suggested an important
role for autophagy impairment in Parkinson’s Disease (PD). Genetic studies have identified mutations in genes
encoding for components of the autophagy-lysosomal pathway (ALP), including glucosidase beta acid 1 (GBA1), that
are associated with increased risk for developing PD. Observations in PD brain tissue suggest an aberrant regulation of
autophagy associated with the aggregation of α-synuclein (α-syn). As autophagy is one of the main systems involved
in the proteolytic degradation of α-syn, pharmacological enhancement of autophagy may be an attractive strategy to
combat α-syn aggregation in PD. Here, we review the potential of autophagy enhancement as disease-modifying
therapy in PD based on preclinical evidence. In particular, we provide an overview of the molecular regulation of
autophagy and targets for pharmacological modulation within the ALP. In experimental models, beneficial effects
on multiple pathological processes involved in PD, including α-syn aggregation, cell death, oxidative stress and
mitochondrial dysfunction, have been demonstrated using the autophagy enhancers rapamycin and lithium. However,
selectivity of these agents is limited, while upstream ALP signaling proteins are involved in many other pathways than
autophagy. Broad stimulation of autophagy may therefore cause a wide spectrum of dose-dependent side-effects,
suggesting that its clinical applicability is limited. However, recently developed agents selectively targeting core ALP
components, including Transcription Factor EB (TFEB), lysosomes, GCase as well as chaperone-mediated autophagy
regulators, exert more specific effects on molecular pathogenetic processes causing PD. To conclude, the targeted
manipulation of downstream ALP components, rather than broad autophagy stimulation, may be an attractive strategy
for the development of novel pharmacological therapies in PD. Further characterization of dysfunctional autophagy in
different stages and molecular subtypes of PD in combination with the clinical translation of downstream autophagy
regulation offers exciting new avenues for future drug development.
Background
The presence of Lewy bodies (LBs) and Lewy neurites,
intraneuronal and axonal inclusions consisting of aggre-
gated α-synuclein (α-syn), is the pathological hallmark of
Parkinson’s Disease (PD) and Dementia with Lewy
Bodies (DLB) [1]. This accumulation of α-syn has been
associated with impaired functioning of protein degrad-
ation mechanisms [2, 3]. One of the main routes for the
intracellular degradation of α-syn is autophagy [4, 5], the
lysosome-mediated catabolic process in which dys-
functional organelles and proteins are degraded in
mammalian cells. Autophagy has a pivotal role in the
homeostasis of neurons. Protein quality control and or-
ganelle recycling are particularly important in these cells,
that have abundant oxidative metabolism and generally
do not replicate in adult life. Moreover, reduced function
of autophagy was demonstrated to cause intracellular
accumulation of proteins and neurodegeneration in in
vitro and in vivo experiments [6, 7]. The reliance of neu-
rons on proper functioning of the autophagy-lysosomal
pathway (ALP) is supported by observations that the
brain is often the most severely affected organ in pri-
mary lysosomal storage disorders (LSDs) [8].
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After autophagy was implicated in the degradation of
α-syn, converging evidence from genetic, pathological
and experimental studies has provided indications that
the ALP is compromised in PD [9]. In preclinical model
systems of PD, the increase of autophagic degradation
activity (autophagic flux) by rapamycin and lithium, po-
tent autophagy enhancers routinely used in a laboratory
setting, resulted in increased clearance of α-syn and neu-
roprotective effects, which were primarily related to in-
creased autophagy [10]. After these initial findings,
similar effects were shown in different preclinical models
of PD using other agents that stimulate autophagy, in-
cluding metformin and trehalose [11]. These studies to-
gether suggested a role of autophagy deregulation in the
occurrence of different modeled PD-related pathological
processes, and suggested that the pharmacological en-
hancement of autophagy holds promising potential for
the development of disease-modifying therapies in PD.
However, the selectivity for most of these agents is lim-
ited, while upstream ALP components are involved in
many other pathways than autophagy. In the context of
neurodegenerative disease, in which high-dosage long-
term therapies are necessary in order to exert effects in
the brain, the broad stimulation of autophagy could
therefore result in a wide spectrum of side-effects.
Recently, however, several agents that selectively target
more downstream ALP components have been developed,
which opens up exciting perspectives to combat specific
molecular pathogenetic processes relevant for PD.
This study focuses on the emerging role for dysfunc-
tional autophagy in PD, discusses potential molecular
targets in the ALP and reviews the evidence obtained in
preclinical model systems of PD using autophagy-
enhancing strategies, in order to determine the potential
of targeted autophagy modulation as disease-modifying
therapy in PD.
Molecular regulation of autophagy
So far, three types of autophagy have been identified based
on routes that differ in the way in which substrates even-
tually reach the lysosomal lumen: microautophagy,
chaperone-mediated autophagy (CMA) and macro-
autophagy. In microautophagy, cytosolic substrates are
engulfed directly by the lysosome, after deformation of the
lysosomal membrane, in a non-specific way [12]. Macro-
autophagy is a degradation pathway that involves the for-
mation, elongation and nucleation of double-membrane
organelles - called autophagosomes - by which the sub-
strate is sequestered, before fusion with lysosomes [13]. Fi-
nally, chaperone-mediated autophagy (CMA) is a highly
specific process in which soluble cytosolic proteins con-
taining a KFERQ-related targeting motif are recognized by
a chaperone-complex involving the heat-shock cognate
protein of 70 kDa (Hsc70). The substrate is subsequently
translocated to and internalized by the lysosomal-
associated membrane protein 2a (LAMP2a) receptor [14].
Under normal conditions, CMA and macroautophagy
occur constitutively at low levels, while these processes
are triggered under conditions of cellular stress, including
starvation, oxidative stress and presence of protein aggre-
gates [13]. While CMA is characterized by its high specifi-
city, macroautophagy has originally been considered a
nonspecific bulk degradation pathway. However, a grow-
ing number of selective, specialized types of macroauto-
phagy are described which are generally named to the
cargo destined for degradation, for instance the targeted
degradation of mitochondria (mitophagy), peroxisomes
(pexophagy), the endoplasmic reticulum (ER; reticulo-
phagy), ribosomes (ribophagy), lipid droplets (lipophagy)
and many more [15]. These specialized forms of macroau-
tophagy have their own degradation cues and specific
ubiquitin-dependent or independent autophagy receptors
(reviewed in [16, 17]).
Macroautophagy is an evolutionary highly conserved
process and its molecular pathways have been well-
characterized after the discovery of autophagy-related
genes (ATGs) in Saccharomyces cerevisiae (reviewed in
Bento et al. [18]). The mammalian target of rapamycin
(mTOR), a 289-kDa serine/threonine kinase, has been
identified as a master regulator of macroautophagy, that
can be embedded in two protein complexes: mTORC1
or mTORC2. Macroautophagy is negatively regulated by
mTORC1, while mTORC2 is primarily involved in regu-
lation of cellular survival and cytoskeletal organization
[19]. Situations of amino acid deprivation relief the
direct inhibition of mTORC1 on a protein complex
involving UNC-51-like kinase 1 (ULK-1), Atg13 and
FIP200, leading to macroautophagy initiation (Fig. 1)
[20]. Binding of growth factors or insulin to their corre-
sponding receptors activates the PI3K class 1 protein
complex, which can activate mTORC1 via Akt and the
tuberous sclerosis complex (TSC1/TSC2 complex) [21].
The activation of PI3K class 1 further results in the in-
hibition of a macromolecular protein complex including
PI3K class 3 (Vps34), Beclin-1 and ATG14L [22], which,
when stimulated, promotes autophagosomal membrane
nucleation [23]. AMP activated protein kinase (AMPK)
detects the intracellular ratio between ATP and AMP and
low amounts of energy result in AMPK activation. AMPK
activation exerts an inhibiting effect on mTORC1 via the
TSC1/TSC2 complex, or in direct phosphorylation of
ULK-1, both resulting in the initiation of autophagy [24].
In this way, eukaryotic cells are equipped with a mechan-
ism in which the initiation of autophagy is tightly coupled
to cell growth regulation via either inhibition or stimula-
tion of mTOR.
The transcription factor EB (TFEB) has been identified
as key regulator of biogenesis and function of lysosomes
Moors et al. Molecular Neurodegeneration  (2017) 12:11 Page 2 of 18
and functions downstream of mTORC1 [25, 26]. In rest-
ing cells, TFEB is localized at the cytosol, where it inter-
acts with mTORC1 and the lysosomal vacuolar-type
ATPase complex. The inhibition of mTORC1 activity
results in dephosphorylation of TFEB, which then trans-
locates to the cell nucleus and binds to the lysosome-
related genes of the CLEAR network, activating a de
novo gene transcription [27, 28].
In addition to the mTOR-dependent pathways, macro-
autophagy can be initiated by a pathway working inde-
pendent of mTOR (Fig. 1) [29]. This pathway, involving
Ca2+-calpain-G-stimulatory protein α (Gsα) and cAMP-
Epac-PLC-ε-inositol signaling, 1,4,5-triphosphate (IP3)
acts as a negative mTOR-independent regulator of
macroautophagy [30]. The generation of IP3 from PIP2,
which is mediated by PLC-ε, results in the release of cal-
cium from the endoplasmatic reticulum (ER). The subse-
quent activation of calpains leads to cleavage of Gsα and
inhibition of macroautophagy. In addition, the conver-
sion of IP3 induces a chain reaction resulting in the
production of Inositol monophosphatase (IMPase) and
Inositol (Ins), which also inhibits autophagic processes.
In turn, a decrease of IP3 leads to reduced calcium re-
lease and AMPK activation, which ultimately results in
autophagy induction.
Converging evidence for a role of ALP
dysfunction in PD
Genetic studies
A substantial amount of recently identified genetic fac-
tors has been shown to be involved in or to interact with
the ALP, as was reviewed by Gan-Or et al. [31]. Approxi-
mately a decade ago, the association between glucosidase
beta acid 1 (GBA1) mutations and PD was described.
Homozygous mutations in the GBA1 gene, which en-
codes for the lysosomal hydrolase glucocerebrosidase
(GCase), lead to Gaucher Disease (GD), the most com-
mon LSD. Although parkinsonism is a rare feature in
patients with GD, several GD patients with parkinsonism
had relatives with a typical, late-onset form of PD [32].
After confirmation of this observation in large-scale
multicenter studies [33] and meta-analyses [34, 35], the
presence of pathogenic heterozygous mutations in this
gene is now considered as one of the most important
Fig. 1 Molecular regulation of macroautophagy and targets for pharmacological stimulation of the autophagy-lysosomal pathway. Situations of amino
acid deprivation and low amounts of energy, detected by AMPK, can lead to the inhibition of mTORC1, resulting in the initiation of autophagy via
activation of the ULK1-FIP200-Atg13 complex. In this situation, TFEB is dephosphorylated and translocates to the cell nucleus where it binds to ATGs to
activate de novo gene transcription. Deprivation of growth factors or insulin results in reduced activation of the PI3K Class 1 complex, which promotes
the formation of autophagosomes via activation of the Beclin-1-VSP34 complex. A final mTOR-independent pathway, involving the generation of IP3,
acts as a negative regulator of autophagy. A number of autophagy-enhancing agents, shown in red, is yet available, allowing to act at different levels
of the autophagy-lysosomal pathway
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risk factors to develop PD. It is estimated that the preva-
lence of PD patients with GBA mutations is 5–10%,
while this percentage can be higher in certain popula-
tions [36].
Several other lysosomal genes have been associated
with PD [37]. Genome-wide association studies have re-
peatedly reported an association between scavenger re-
ceptor class B member 2 (SCARB2) with reduced risk to
develop PD [31]. SCARB2 encodes for the lysosomal in-
tegral membrane protein type 2 (LIMP2), which inter-
acts with GCase and is responsible for its transport to
the lysosome [38]. The sphingomyelin phosphodiesterase
1 (SMPD1) gene encodes for the lysosomal enzyme acid
sphingomyelinase (aSMase), which converts sphingo-
myelin into ceramide. The association of variants of
SMPD1 with increased risk to develop PD has now been
repeatedly reported [39–42]. However, SMPD1 muta-
tions are rare and more studies are needed to determine
their significance in PD. Mutations in the ATP13A2
(PARK9) gene, encoding a lysosomal ATPase, cause a
rare form of atypical, juvenile-onset autosomal recessive
parkinsonism with pyramidal neurodegeneration and de-
mentia - the Kufor-Rakeb syndrome. Finally, some other
LSDs have been associated with parkinsonism, including
Niemann-Pick type C, Sanfilippo A, GM1 and GM2
gangliosidoses, and Fabry Disease [37]. However, these
associations are often based on observations in small
patient groups and thus most likely only relevant for
very small subpopulations of PD patients.
Apart from mutations in genes that directly encode for
lysosomal components, direct and indirect roles have been
proposed for numerous other PD-related mutations in the
process of autophagy. A rare form of autosomal dominant
PD is caused by mutations in the gene encoding vacuolar
protein sorting protein-associated protein 35 (VPS35),
which is involved in endosomal-lysosomal trafficking, a
process functionally associated with autophagy [31, 43].
Moreover, numerous autosomal recessive PD genes, in-
cluding Parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7)
and Fbxo7 (PARK15) were found to be implicated in mito-
phagy, which is the degradation of dysfunctional mito-
chondria by autophagy [31, 44]. Mutations in the leucine-
rich repeat kinase 2 (LRRK2) gene are among the most
common risk factors for PD together with GBA1 muta-
tions. Lrrk2 can both be degraded by CMA [45] and
macroautophagy [46], but mutated forms of this protein
impair CMA function leading to accumulation of sub-
strates, including α-syn [45]. Lrrk2 has also been proposed
to have a more general role in autophagy as well, as the ac-
cumulation of autophagic vacuoles was observed in a cellu-
lar model transfected with mutated LRRK2 [47]. However,
the exact role of Lrrk2 in this process remains elusive [31,
43]. Finally, some proteins encoded by other PD-related
genes, including SNCA and MAPT, were shown to interact
with components of the ALP, thereby modifying the func-
tioning of autophagy [31].
Together, genetic studies have demonstrated that nu-
merous genetic risk factors for PD are directly involved
in the functioning of the ALP or mitophagy [31], while
for other genetic forms of PD, for instance caused by
LRRK2, MAPT and SNCA mutations, functional interac-
tions of their gene-products with components of the
ALP were demonstrated. However, it is important to
note that the prevalence of most of the mutations de-
scribed here in PD is low, and that they do not necessary
lead to PD. The genetic studies further suggest that dys-
functional autophagy in PD can have different under-
lying gene-deficits.
Pathological studies
After accumulation of autophagic vacuoles in the post-
mortem SN of PD patients was first described [48],
subsequent postmortem studies demonstrated altered
expression of numerous ALP components in the PD
brain compared to age-matched controls [49]. Increased
levels of microtubule-associated protein 1 light chain 3
(LC3), a marker for autophagosomes, have been ob-
served in the SN of PD patients [50] as well as in the
temporal cortex of patients with Dementia with Lewy
Bodies [51]. Furthermore, lysosomal depletion was indi-
cated by decreased levels of lysosomal-associated mem-
brane protein type 1 (LAMP1) in the SN of PD patients
[50, 52]. Lower levels of the CMA markers LAMP2a and
the chaperone Hsc70 have further been observed in
various regions of the PD brain compared to controls
[53, 54], suggesting CMA deregulation. In addition, the
deregulation of lysosomal enzymes, in particular GCase,
has been demonstrated in different brain regions [55–57]
and CSF [58–60] of PD patients compared to controls,
while increased immunoreactivity of the GCase-interactor
LIMP2 was observed in dopaminergic neurons in the SN
of PD patients [61]. Altered enzyme activities in the PD
brain have not only been observed for GCase, but also for
cathepsin A and cathepsin D [52, 56]. For cathepsin D, in-
creased [56] and decreased [52] activities were reported in
the PD cingulate cortex and SN, respectively, while no
changes were found in the frontal cortex [62]. Finally,
contradictory results were obtained for P-type ATPase
(ATP13A2) in the frontal cortex of PD and DLB patients,
for which both decreased [63] and increased [64] protein
levels have been reported compared to controls. In the
striatum of PD and DLB patients, increased ATP13A2
protein levels were found [64].
A deregulation of the ALP in the PD brain was re-
cently demonstrated by transcriptome studies [65–67].
Alterations for numerous autophagy-related processes,
including mTOR signaling, PI3K/AKT signaling and 14-
3-3 protein signaling, have been reported in postmortem
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SN tissue as well as in peripheral blood mononuclear
cells (PBMCs) of PD patients [65–67]. The deregulation
of the mTOR-dependent pathway in synucleinopathies
was underscored by the finding that mTOR protein ex-
pression levels were increased in the temporal cortex of
patients with DLB in comparison to controls, in particu-
lar in neurons displaying α-syn accumulation [68]. Alter-
ations in other upstream autophagy-related proteins
were demonstrated in brain tissue of patients with PD
and DLB compared to controls [69]. Immunoreactivity
of ULK-1, ULK-2, VPS35 and autophagy/Beclin-1 regula-
tor 1 (AMBRA1) was shown within mature LBs [69]. No
differences in protein expression levels were observed
for these proteins in SN tissue of PD patients, although
VPS35 levels were found increased in the temporal cor-
tex of DLB patients [69]. Beclin-1 protein expression
levels were found increased in SN tissue [69], but de-
creased in the cingulate cortex of patients with PD [56].
In the postmortem SN of PD patients, the subcellular
localization of TFEB was changed, as TFEB expression
in the nuclear department of dopaminergic neurons was
significantly decreased in PD patients compared to con-
trols [70]. Moreover, TFEB co-localized with LBs in the
same region [70].
In conclusion, pathological studies have shown some
evidence for altered ALP protein levels and lysosomal
enzyme activity in PD and DLB. However, the reported
alterations are generally subtle and sometimes inconsist-
ent, with large overlap between patients and aged con-
trols. Additionally, these pathological studies often also
show tremendous variability within the group of PD pa-
tients. Together, this may indicate that multiple patho-
logical processes may underpin dysfunctional autophagy
in PD or that autophagy is impaired in a subpopulation
of PD patients. Moreover, so far, most studies have only
focused on the SN of PD patients [49]. As some of the
results suggest a differential regulation of autophagy
markers between different brain regions, systematic
studies that map the distribution of lysosomal and au-
tophagy markers in different stages and molecular sub-
types of PD is needed.
Interactions between autophagy and α-syn
Experimental studies have identified the ALP as key
player in the clearance of α-syn. Both the ubiquitin-
proteasomal system (UPS) and autophagy were found to
be implicated in the clearance of wild-type (WT) α-syn
in PC12 cell lines, as the inhibition of both processes
results in its accumulation [4]. WT α-syn contains the
CMA-targeting motif required for Hsc70 recognition,
suggesting that its autophagic degradation is associated
with CMA activity. Although its clearance can also be
partially mediated by macroautophagy, this system may
not be of crucial importance in this process [71].
However, a more important role for macroautophagy
has been suggested in situations of increased α-syn bur-
den [37], as macroautophagy has been implicated in the
clearance of α-syn oligomers [72], as well as mutant [73]
and post-translationally modified forms of α-syn, in
cellular [74] and yeast [75] models of PD.
Several studies have further shown the possible in-
volvement of lysosomal enzymes in α-syn degradation.
First, genetic or pharmacological reduction of GCase
activity results in the accumulation of α-syn in in vitro
[76, 77], in mice [77], as well as in a transgenic mouse
model of GD [78]. Additionally, the depletion of both
GCase and cathepsin D lead to enhanced cell-to-cell
transmission of α-syn aggregates in vitro, suggesting a
role for these enzymes in the spreading and propagation
of synucleinopathy [79, 80]. Together, these studies have
shown an intimate relation between autophagy, lyso-
somal enzymes and α-syn turnover. The verification of
macroautophagy and CMA contributions in the turnover
of different forms of α-syn in vivo, under physiological
and pathological conditions, is ongoing [5].
Stimulating macroautophagy in preclinical models
of PD
Approximately a decade ago, pioneering studies have ex-
plored the chemical stimulation of the ALP in PD model
systems using rapamycin and lithium, substances that are
routinely used to trigger autophagy in vitro. After this,
numerous studies have tested the effects of other
autophagy-enhancing agents on different modeled PD-
related pathological processes. The following section high-
lights preclinical studies in which effects of chemical
agents in preclinical PD models were primarily associated
with increased autophagy (summarized in Table 1).
Pioneering studies: Rapamycin and lithium
The most thoroughly tested macroautophagy-enhancer
is rapamycin, a metabolite isolated from the bacterial
strain Streptomyces hygroscopicus. The drug inhibits the
upstream signaling factor mTOR by binding to its intra-
cellular FKBP12 receptor, thereby disrupting the ability
of mTOR to form assemblies with RAPTOR and block-
ing mTORC1 signaling [10, 81]. Rapamycin was able to
reduce α-syn accumulation and blocked α-syn induced
neurodegeneration in wild-type, A30P, or A53T α-syn ex-
pressing PC12 cells [4] and in α-syn-overexpressing mice
[68] and rats [70], respectively. Rapamycin further reduced
cell death in cell lines treated with 6-OHDA and rotenone
[82, 83], and reduced neuronal death in the methyl-4-
phenyl-1,2,3,6 tetrahydropyridine (MPTP) mouse model
of PD [50, 83]. In addition, rapamycin improved motor
function in A53T α-syn overexpressing mice [84] and re-
lieved L-Dopa-induced dyskinesias in 6-OHDA-treated
mice and rats without affecting the therapeutic efficacy of
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Table 1 Reported effects of autophagy-enhancing agents in preclinical PD models
Target Agent Main effect PD model Ref
mTOR-dependent
pathways









AMPK AICAR Reduced cell death LRRK2-mutated Drosophila
Melanogaster
[95]
AMPK (SIRT1) Resveratrol Increased α-syn clearance α-Syn overexpressing PC12
cells
[100]











increased striatal DA levels
A30P α-syn transgenic mice [140]
Beclin-1 Isorhynchophylline Increased α-syn clearance N2a cells transfected for WT,













mTORC1 Rapamycin and Rp analogues






Reduced cell death Rotenone-exposed SH-SY5Y
cells
[82, 92, 93]
6-OHDA and MPP+ treated
PC12 cells
[83]









A53T- α-Syn transgenic mice [84]
Reduced levodopa-induced
dyskinesia







mutated for PINK-1 and
Parkin
[87]
TFEB 2-HPβCD Increased α-syn clearance H4 human neuroglioma cells
transfected for α-syn
[143]
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Table 1 Reported effects of autophagy-enhancing agents in preclinical PD models (Continued)
mTor-independent
pathways
IMPase Lithium Increased clearance of A53T
and A30P α-syn









increased viability DA cells in
the SN, decreased loss of
DOPAC
MPTP mice (combined
treatment with lithium and
sodium valproate)
[94]






increased viability DA cells in
the SN, decreased loss of
DOPAC
MPTP mice (combined
treatment with lithium and
sodium valproate)
[94]





SLC2A transporters Trehalose Reduced cell loss Rotenone-treated rats and
PC12 cells
[107]
MPTP mice; A53T α-Syn
overexpressing rats
[108, 109]















Reduced motor deficits MPTP mice; A53T α-Syn
overexpressing rats
[108, 109]
Reduced neuroinflammation MPTP mice [108]
Unknown SMERs (SMER 10, 18 & 28) Increased A53T α-syn
clearance
PC12 cells expressing A53T
α-syn
[112]
Unknown Latrepirdine Increased α-syn clearance Saccharomyces cerevisiael,
SH-SY5Y cells expressing
α-syn and WT mice
[115]
Decreased cell death Saccharomyces cerevisiae
expressing α-syn
[115]










Curcumin Reduced α-syn accumulation SH-SY5Y Cells expressing WT
and A53T α-syn
[119]
Kaempferol Reduced ROS, apoptosis, and
mitochondrial dysfunction
Rotenone-exposed SH-SY5Y
cells, mouse primary neuronal
culture
[120]
C. album polyphenol fractions Reduced α-syn accumulation;
reduced ROS
Hu neuroglioma H4 cells
expressing αSyn;
Yeast cells expressing αSyn
[121]






Reduced cell death Mice expressing A53T
α-synuclein
[122]
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L-Dopa [85, 86]. Finally, rapamycin showed neuro-
protective effects in Drosophila melanogaster mutated for
PINK-1 and Parkin [87]. However, rapamycin interferes in
numerous other pathways than autophagy, while pro-
longed treatment with rapamycin can lead to the inhib-
ition of mTORC2, thereby possibly stimulating other
important cellular pathways, for instance influencing cell
survival mechanisms. In addition, the use of rapamycin
has been associated with a wide spectrum of side-effects,
including oral and respiratory infections, stomatitis,
leukopenia, hypertriglyceridemia, hypercholesterolemia
and immunosuppression [10].
Lithium, which is in use as a mood stabilizer in the treat-
ment of bipolar disorders, is able to induce autophagy in an
mTOR-independent manner by direct non-competitive in-
hibition of IMPase [88]. The neuroprotective effects of lith-
ium in in vivo and in vitro models have repeatedly been
reported [89]. However, lithium interferes with many other
cellular pathways as well, and numerous mechanisms of ac-
tion have been proposed for this drug [90]. The use of lith-
ium in bipolar disorders revealed that the drug is associated
with a wide spectrum of dose-dependent side-effects, for
instance including fine hand tremor, hypothyroidism,
hypercholesterolemia, hyperparathyroidism, and hypercal-
cemia [91]. In preclinical PD models, lithium prevented ac-
cumulation of α-syn in PC12 cells expressing A53T and
A30P α-syn [88] and protected against rotenone-induced
neurotoxicity and cell death via the induction of autophagy
in different cell lines [92, 93]. Two other mood-stabilizing
agents - sodium valproate and carbamazepine—were dem-
onstrated stimulate autophagy independently from mTOR
via Ins, which is downstream of IMPase [92]. Both sodium
valproate and carbamazepine were shown to decrease rote-
none toxicity and to induce autophagy in SH-SY5Y cells
[92]. Moreover, combined treatment of sodium valproate
with lithium alleviated motor impairments in MPTP mice,
while it protected SN dopaminergic neurons [94]. However,
similar to lithium, these agents are non-selective for au-
tophagy and acts on many other cellular pathways as well,
possibly resulting in a numerous unwanted effects.
Together, preclinical studies using rapamycin and
lithium showed beneficial effects on different modeled
PD-related pathological processes, including α-syn
aggregation, mitochondrial dysfunction and oxidative
stress, which were associated with increased autophagy.
Both agents affect many other cellular processes than
autophagy, and their side-effect profile makes them un-
suited for prolonged high-dosage therapies. However,
these pioneering studies have provided important in-
sights into the role of autophagy in PD-related patho-
logical processes, and demonstrated the potential of
autophagy-enhancing strategies in experimental settings.
Other targets for macroautophagy enhancement
AMPK
Activation of AMPK, the signaling factor upstream of
mTORC1, leads to the inhibition of mTORC1 and
initiation of autophagy. Numerous agents are associated
with the activation of AMPK, including metformin,
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)
and resveratrol. The administration of metformin, which
is used in Diabetes Mellitus, showed neuroprotective
effects in in vitro and in two in vivo models of PD: dros-
ophila with mitochondrial dysfunction and MPTP mice
[95–97]. Further, metformin decreased Ser-129 phosphor-
ylated α-syn levels in α-syn overexpressing SH-SY5Y cells
[98]. Similar results have been reported using AICAR, an
drug used in the treatment of acute lymphoblastic
leukemia [95–97]. Resveratrol activates AMPK after inter-
action with its direct target SIRT1 and protective effects
of this compound have been reported in different in vitro
and in vivo models of PD [99–102], some of which were
associated with increased autophagy [100–102].
Trehalose is a disaccharide that inhibits members of
the SLC2A (also known as GLUT) family of glucose
transporters, leading to an AMPK-dependent - and
mTOR-independent - increase in autophagy [103, 104].
The beneficial effects of this drug for cell survival
and α-syn clearance have been shown and associated to
increased autophagy in different cell lines [104–106] as
Table 1 Reported effects of autophagy-enhancing agents in preclinical PD models (Continued)
Lysosomes GCase Ambroxol Restoration of lysosomal
function;
increased GCase activity
GBA1 mutant fibroblasts [150, 151]
Reduction of oxidative stress GBA1 mutant fibroblasts [150]







Lysosome Acidic Nanoparticles Restoration of lysosomal





Abbreviations: Ref reference number, 2-HPβCD 2-Hydroxypropyl-β-cyclodextrin, α-syn α-synuclein, DA dopaminergic, DOPAC 3,4-Dihydroxyphenylacetic acid,
ROS reactive oxidative stress, WT wild-type, 6-OHDA 6-hydroxydopamine, MPTP 1-methyl-4-fenyl-1,2,3,6-tetrahydropyridine, UPS ubiquitin-proteasomal system
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well as in multiple in vivo models [107–110]. As trehalose
is digested by trehalase into glucose in the small intestine,
liver and kidney, its bioavailability in the brain may be lim-
ited. Recently, two novel trehalase-indigestible and
autophagy-inducing disaccharides were developed, which
were shown to reduce polyglutamine aggregation in vitro,
highlighting the anti-aggregation properties of these
agents [111], which, to our knowledge, have not been
tested in preclinical models of PD, yet. In sum, AMPK-
dependent increase of autophagy showed beneficial effects
on different modeled pathological processes in PD. How-
ever, importantly, as cellular energy sensor, AMPK is in-
volved in various other key cellular processes, including
cell proliferation and survival. Therefore, the global ma-
nipulation of its function is likely to induce unwanted ef-
fects, and limits its therapeutic potential in the context of
PD.
Other macroautophagy-enhancing agents
A chemical screening approach has resulted in the dis-
covery of three small-molecule enhancers of rapamycin
(SMERs): SMER10, SMER18 and SMER28 [112]. These
agents induced autophagy and enhanced clearance of
mutant A53T α-syn in a PC12 cell line in an mTOR-
independent way [112]. Although SMERs have shown
promising potential in PD model systems, their specific
biochemical pathways remain to be characterized [113].
The antihistamine latrepirdine was shown to enhance au-
tophagy [114] and to attenuate accumulation of α-syn both
in vivo and in vitro systems [115]. Latrepirdine entered
phase 3 clinical trials for both Alzheimer’s disease (AD)
and HD [116], in which was well-tolerated without signifi-
cant toxicity it failed to show efficacy compared to placebo
(more information available on: https://clinicaltrials.gov/).
Although latrepirdine was suggested to act preferentially
on α-syn [117], it probably intervenes in many cellular pro-
cesses, while its biochemical pathways are currently un-
clear [116]. Finally, numerous studies have associated
beneficial effects in preclinical models of PD of other com-
pounds, for instance including spermidine [118], different
dietary polyphenols other than resveratrol [119–121] and
tyrosine kinase inhibitors [122, 123], with increased macro-
autophagy. However, the exact mechanisms of action for
these compounds require further investigation, and these
agents may affect many other cellular processes other than
autophagy.
Macroautophagy: a double-edged sword
Together, studies using macroautophagy-enhancing
agents in preclinical models of PD have demonstrated
that the broad stimulation of autophagy can result in the
alleviation of different modeled PD-related pathological
processes, such as cell death, α-syn aggregation, oxida-
tive stress and mitochondrial dysfunction (Table 1).
However, the clinical translation of these findings is
problematic, given that the selectivity of these agents for
autophagy is limited, while upstream ALP signaling
proteins are involved in many pathways other than
autophagy - for instance including apoptosis, cell growth,
and immune responses. This lack of selectivity may limit
the therapeutic potential of broad autophagy stimulation,
as it may result in unwanted effects. Long-term effects
and side-effects of broad stimulation of macroautophagy
are currently unknown, and more insight in these effects
is of crucial importance before application of prolonged
high-dose therapies in a clinical setting. In particular, the
intimate relation between macroautophagy and apoptosis
should be carefully considered. Although macroautophagy
and apoptosis comprise two distinct cellular processes,
various shared components and mechanisms have been
identified by which autophagy and apoptosis regulate each
other [124].
Another important danger of broad macroautophagy
enhancement is the complex dual role for autophagy in
specific contexts. For example, autophagy can have
tumor-suppressive, neutral, or tumor-promiting effects
in different types and stages of cancer [125]. Although
autophagy can act as tumor suppressor, for instance by
the removal of damaged organelles, autophagy stimula-
tion can also promote the growth of established cancers
in certain contexts [125, 126]. Indeed, excessive stimula-
tion of macroautophagy under specific circumstances
has been associated with detrimental effects. First, the
observation of a specific type of cell death characterized
by extensive autophagic vacuolization of the cytoplasm
in PD postmortem brain tissue [48] has led to the highly
debated concept of ‘autophagic cell death’. In various in
vitro model systems of PD, autophagic cell death was re-
ported in cells treated with excessive levels of dopamine
[127], A53T α-syn [128] and oxidative stress [129].
Moreover, treatment with rapamycin in presence of
oxidative stress reduced cell viability [129], while the
activation of AMPK has been reported to induce cell
death in different in vitro models of PD [130].
The activation of macroautophagy has further been as-
sociated with the shortening of neurites in a 6-OHDA
mouse model, while the indirect activation of mTOR by
the inhibition of Akt was able to suppress the retrograde
axonal degeneration [131]. Autophagy was further asso-
ciated with neurite degeneration in LRRK2-mutant SH-
SY5Y cells [47] as well as in mouse superior cervical
ganglion neurons [132]. Overexpression of both WT and
A53T α-syn in SH-SY5Y and PC12 cell lines resulted in
a gradual increase in toxicity, mediated by impairment
of CMA [133]. The induction of macroautophagy in
these models led to neuronal death, indicating that a
compensatory upregulation of macroautophagy under
the circumstances of increased α-syn burden can have
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detrimental effects [133]. Furthermore, the activation of
macroautophagy in primary cortical neurons overexpress-
ing A53T α-syn caused mitochondrial destruction and
loss, as well as neuronal degeneration [134]. Finally, an-
other form of autophagy-dependent cell death – autosis -
was recently described, although its exact mechanisms
remain unclear [135].
Taken together, these experimental findings demon-
strated that activation or stimulation of macroautophagy
can have detrimental effects under specific circum-
stances. Maintaining the balance between protective and
detrimental effects is therefore of vital importance in
therapeutic approaches to stimulate broad autophagy
[136], which implies extensive knowledge about dosage
and timing for such therapies and may limit their
current therapeutic applicability.
Selective targeting of ALP components
Beclin-1
The activation of Beclin-1 leads to autophagosome for-
mation and initiation of autophagy, independent from
mTOR (Fig. 1). Gene-transfer induced overexpression of
Beclin-1 was able to reduce accumulation of α-syn in
α-syn overexpressing mice [137] and PC12 cells [138],
suggesting that the Beclin-1 pathway may be a viable thera-
peutic target in PD. Although numerous drugs have been
associated with increased Beclin-1 activity, including tam-
oxifen, Beclin-1 expression mimetics (BH3 mimetics) and
the peptide Tat-Beclin-1, only few studies tested pharmaco-
logical Beclin-1 stimulation in PD models [139–141]. One
study showed protective effects of tamoxifen, a drug widely
used in the treatment of breast cancer, in a MPP+ rat
model, in which it suppressed radical generation [139].
However, this effect was not attributed to increased
autophagy. Another study reported that the inhibition
of prolyloligopeptidase (PREP) resulted in a Beclin-1-
dependent increase of autophagy together with a re-
duction of α-syn aggregates in cell models and α-syn
transgenic mice [140]. Finally, isorhynchophylline, a
natural alkaloid, was reported to promote the clear-
ance of WT, A53T and A30P α-syn monomers, as
well as oligomeric and aggregated forms of α-syn in
neuronal cell lines, in which its autophagy-enhancing
activity was shown to be Beclin-1-dependent [141].
As the BH-3 domain of Beclin-1 interacts with the
pro-survival BCL-2 family members, it was expected
that binding of Beclin-1 to BCL2 would induce apop-
tosis, potentially resulting in undesired side-effects
[126]. However, overexpression of Beclin-1 does not
result in induction or enhancement of apoptotic pro-
cesses, which suggested that the functional interaction
of Beclin-1 and BCL-2 is unidirectional, resulting in
inhibitory effects on autophagy without modifying
apoptotic processes [126].
Macroautophagy stimulation downstream of mTOR
As the main transcriptional regulator of the CLEAR net-
work, which coordinates biogenesis and function of lyso-
somes, TFEB is a crucial link between the upstream
signaling pathways that regulate macroautophagy and
lysosomes [26]. Therefore, TFEB forms an attractive
target to stimulate macroautophagy downstream of
mTOR, by intervening at the transcriptional level (Fig. 2).
The first approaches to stimulate TFEB in PD models
have yielded promising results. Overexpression of TFEB
was demonstrated to eliminate α-syn oligomers and to
rescue midbrain dopamine neurons from α-syn toxicity
in α-syn overexpressing rats [70]. In addition, delayed
activation of TFEB via inhibition of mTORC1, achieved
using a derivate of rapamycin (CCI-779), alleviated α-
syn pathology and was associated with increased autoph-
agic markers and the nuclear translocation of TFEB [70].
2-Hydroxypropyl-β-cyclodextrin enables the chemical
activation of TFEB [142], and was recently shown to
promote autophagic clearance of α-syn [143]. These
findings provided a mechanistic link between TFEB
function and α-syn aggregation, highlighting the role of
TFEB in synucleinopathy and the potential of TFEB-
activating strategies to combat α-syn aggregation in PD.
Direct targeting of lysosomes
The modulation of lysosomes has recently emerged as an
attractive strategy to selectively stimulate the ALP in PD.
Recent work showed that acidic nanoparticles were able
to stimulate lysosomal degradation by the lowering of
lysosomal pH [144], reverting lysosomal dysfunction in
three different PD genetic models, including ATP13A2-
mutant cells and GBA-mutant cells [145]. Moreover,
acidic nanoparticles attenuated dopaminergic cell death in
MPTP-treated mice, providing evidence for the feasibility
of such strategies in vivo [145]. These findings highlight
the potential of pharmacological interventions on the lyso-
somal system.
Another interesting approach is the direct targeting of
specific lysosomal enzymes such as GCase to stimulate
the intralysosomal degradation of α-syn. Restoration of
GCase expression by an adeno-associated virus reduced
α-syn aggregation and, interestingly, its expression in the
hippocampus was able to reverse cognitive impairment
in a GD mouse model [78, 146, 147]. As results from the
enzyme-replacement therapies in GD show that GCase
does not cross the blood-brain barrier (BBB), the devel-
opment of small-molecule chaperones to correct the
folding of GCase - thereby enhancing GCase activity and
lysosomal function - is currently a topic of great interest
[148]. Small-molecule chaperones specifically target the
misfolded GCase trapped in the ER, stabilizing the active
form of the enzyme and increases trafficking of GCase
to lysosomes (Fig. 2) [149].
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The pharmacological chaperone ambroxol, which has
been in use for airway diseases, was shown to increase
GCase activity and reduce oxidative stress in PD fibro-
blasts carrying GBA1 mutations [150]. Furthermore,
ambroxol was shown to restore Cathepsin D, LIMP2
and Saposin C levels [151], which are essential for the
proper functioning of GCase [149, 152]. In this study,
ambroxol acted preferentially on lysosomal dynamics, as
it did not interfere with Parkin levels or proteasome 20S
activity [151]. Although ambroxol was initially expected
not to have CNS effects at clinically used doses [153],
the drug was reported to cross the BBB in mice [154].
Recently, a pilot study carried out in neuronopathic
GD patients showed that high-dose oral ambroxol
could cross the BBB, being also well-tolerated, in
addition to enzyme-replacement therapy. In these pa-
tients, ambroxol increased lymphocyte GCase activity, re-
duced CSF glucosylsphingosine levels and was associated
with improvements in myoclonus, seizures and pupillary
light reflex dysfunction. Accordingly, ambroxol represents
an interesting candidate waiting for clinical trials in PD.
Other small-molecule chaperones such as AT2101
(isofagomine) as well as histone deacetylase inhibitors
have been reported to increase GCase levels in GD mouse
models and fibroblasts [155–158], and are currently tested
in the context of PD. Additionally, the administration of
isofagomine to human WT-α-syn overexpressing mice
improved motor performance, reduced α-syn immunore-
activity in nigral dopaminergic neurons and reduced in-
flammatory microglial activation [159].
Together, small chaperone activity-enhancers of GCase
were demonstrated to improve lysosomal function and
enhance α-syn clearance in preclinical models of PD.
However, a disadvantage of these chaperones is that they
inhibit GCase activity by binding the catalytic site of the
enzyme, suggesting that the balance between chaperone
functions and inhibitory activity should be carefully con-
sidered when using these compounds [149]. Therefore,
molecular chaperones that do not bind the catalytic site
of GCase are required to exert maximal effects. Recently,
a high throughput screening has led to the identification
of pyrazolopyrimidine derivatives that did not inhibit
GCase, but still facilitated its translocation to the lyso-
some [160]. These agents were able to enhance GCase
activity, reduce substrate accumulation and normalize
oxygen species production in a macrophage model of
Fig. 2 Strategies to combat α-synuclein aggregation by the downstream enhancement of autophagy. Oligomeric and mutant forms of α-synuclein
impair CMA functioning in PD, which may be alleviated by the recently developed retinoic acid alpha receptor inhibitors (RA-α-R inhibitors). The
intralysosomal presence of α-synuclein further results in impaired GCase functioning, while it blocks the transport of GCase from the ER to the
lysosome. Together, these processes lead to reduced GCase hydrolase activity and lysosomal dysfunction in PD. Small-molecule GCase chaperones,
including ambroxol and isofagomine, specifically target the misfolded GCase trapped in the ER to increase trafficking of GCase to lysosomes. Acidic
nanoparticles improve lysosomal functioning by lowering the pH within the lysosomal lumen
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GD [161]. Another recent study identified a small-
molecule noninhibitory chaperone of GCase (NCGC607)
by high-throughput screening [162]. This chaperone was
demonstrated to restore GCase activity and protein
levels and reduced substrate levels, while it reduced α-
syn levels in iPSC-derived dopaminergic neurons [162].
This study underscores the potential of small-molecules
targeting GCase activity and protein to prevent or re-
duce accumulation of α-syn levels in vitro.
Targeting chaperone-mediated autophagy
CMA impairment in PD has been demonstrated by the
lower levels of the CMA markers LAMP2a and the
chaperone Hsc70 in various regions of the PD brain
compared to controls [53, 54], while a central role for
this system is proposed in the degradation of WT α-syn
[5]. An attractive alternative to the stimulation of macro-
autophagy may therefore be the downstream targeting of
CMA components, at the level of LAMP2a and Hsc70.
The overexpression of LAMP2a has been induced in hu-
man SH-SY5Y cells, rat primary cortical neurons in vitro
and nigral dopaminergic neurons in vivo [163]. In these
different models, overexpression of LAMP2a decreased
α-syn accumulation and protected against the α-syn-
induced dopaminergic degeneration [163]. Interestingly,
retinoic acid alpha receptors (RA-α-Rs) were recently
identified as CMA inhibitors and synthetic derivatives of
all-trans-retinoic acid were developed in order to
neutralize this effect [164]. These derivatives were able
to specifically stimulate CMA without a compensatory
blockage of macroautophagy, while LAMP2a was identi-
fied as one of their downstream targets [164]. However,
so far, no studies have reported the chemical modulation
of CMA in preclinical models of PD yet.
Modulation of mitophagy
The involvement of different PD-related genes in mito-
phagy suggest a role for impaired mitochondrial clearance
in PD. By stimulating the removal of damaged mitochon-
dria, the therapeutic stimulation of mitophagy may there-
fore exert neuroprotective effects. However, pharmaceutical
agents that selectively increase mitophagy are currently
lacking. The compounds used in vitro to trigger mito-
phagy, such as trifluorocarbonylcyanide phenylhydrazone
(FCCP) and antimycin/oligomycin combinations, are toxic
and therefore not considered for therapy [165]. The p62-
mediated mitophagy inducer (PMI) may be a promising
chemical candidate, as it is suggested to enhance endogen-
ous levels of mitophagy [166]. However, no effects of this
agent in preclinical models of PD have been described yet.
More insights into the complex dynamics of mitochondria
and the identification of targets able to specifically stimu-
late mitochondrial clearance may allow the development
of innovative neuroprotective therapies for PD and other
neurodegenerative disorders.
Autophagy-related micro-RNAs
In recent years, an important role has been suggested
for micro-RNAs (miRs) in the post-translational regula-
tion of autophagy at various stages of the ALP [167],
which interconnect autophagy with other cellular signal-
ing systems. A recent study showed the down-regulation
of miR-124, which is predicted to regulate 52 genes of
the ALP in a MPTP mouse model [168, 169], while the
delivery of an miR-124 agomir attenuated lysosomal de-
pletion and cell death [169]. A different study demon-
strated an important role for different miRs in the
regulation of CMA markers LAMP2a and Hsc70 [170].
Interestingly, transfection of these miRs resulted in
decreased LAMP2a and Hsc70 protein levels as well as
in significant α-syn aggregation [170]. Moreover, CMA-
related miRNAs were significantly increased in SN and
amygdala of PD patients [170]. A better understanding
of the interaction between miRs and ALP components
and their role in PD may contribute to valuable insights
in autophagy regulation and the cross-talk of autophagy
with other cellular processes, and possibly to future
autophagy-enhancing strategies [169, 170].
The therapeutic value of autophagy enhancers in
PD: considerations and perspectives
The identification of autophagy as key player in the
degradation of α-syn has suggested the potential of
autophagy-enhancing strategies as disease-modifying ther-
apy to combat α-syn aggregation in PD. Indeed, stimula-
tion of autophagy by known autophagy enhancers such as
rapamycin and lithium, resulted in increased α-syn clear-
ance in different α-syn overexpressing preclinical model
systems of PD. Moreover, interestingly, increased autoph-
agy levels were associated with neuroprotective effects in
toxic model systems of PD, as pharmacological autophagy
enhancement ameliorated cell death and mitochondrial
dysfunction, possibly mediated by the increased clearance
of damaged mitochondria (Table 1). Together, pioneering
studies have highlighted potential effects of autophagy-
enhancement on different modeled PD-related pathological
processes. However, selectivity of the early autophagy-
enhancing agents and their targets is limited and broad
macroautophagy stimulation may result in a wide spectrum
of dose-dependent side-effects, making it less suited for
high-dosage long-term therapies. In addition, the broad and
excessive stimulation of macroautophagy under specific, yet
not fully characterized, circumstances can have detrimental
effects, including autophagic cell death.
The recent development of agents selectively target-
ing ALP core components - including TFEB, lyso-
somes and GCase—as well as CMA factors such as
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LAMP2a, enables more specific targeting of pathogenetic
processes, and may harbor more perspective for the devel-
opment of disease-modifying therapies in PD than the
broad activation of macroautophagy. CMA is a highly spe-
cific process that is increasingly recognized as a key sys-
tem in the degradation of WT α-syn [37], which
highlights the demand for the discovery and development
of chemical substances able to specifically stimulate CMA
traffic. Targeting lysosomes or GCase by acidic nanoparti-
cles and small-molecule chaperones, respectively, has
emerged as attractive strategy to encounter lysosomal de-
pletion in PD, representing an area of intensive investiga-
tion. Moreover, the modulation of downstream ALP
components and CMA could lead to more controlled acti-
vation of macroautophagy, as substantial cross-talk takes
place between CMA and macroautophagy [37, 171]. In
the study by McNeill et al., for instance, the GCase
chaperone ambroxol exerted marked effects on TFEB ex-
pression, which suggested that the protective effects were
partially mediated by increased macroautophagy [150]. The
identification of the exact mechanisms underlying the
cross-talk between autophagy pathways, lysosomes and
GCase may allow to identify potential dangers and to deter-
mine optimal efficacy of downstream autophagy-enhancing
approaches.
Establishing the patient selection, optimal dosage, and
timing for maximal therapeutic efficiency will be crucial
next steps in the design of autophagy-enhancing
therapies. Timing of the autophagy-enhancing therapies
may be of particular importance, given the hypothesized
differential roles for proteolytic systems in α-syn degrad-
ation in different stages of aggregation [37]. In vitro ex-
periments suggested that a compensatory upregulation
of macroautophagy under the circumstances of in-
creased α-syn burden can have detrimental effects [133].
LB-like aggregates were further shown to impair macro-
autophagy by blocking clearance of autophagosomes
[172], indicating that excessive macroautophagy stimula-
tion in situations of advanced synucleinopathy may re-
sult in autophagic cell death. A better understanding of
the role of ALP dysfunction in different stages of PD is
therefore essential for the design of future disease-
modifying therapies.
Pathological and genetic studies further suggested that
various molecular and genetic deficits can underlie dys-
functional autophagy in PD. Therefore, the nonspecific
stimulation of autophagy may have differential outcomes
depending on the molecular subtype of PD. For instance,
upregulation of autophagy in the context of lysosomal
dysfunction, in which lysosomal clearance of autophago-
somes is impaired, may lead to further accumulation of
autophagosomes. More insight into the contribution of
dysfunctional autophagy to the progression of these dif-
ferent genetic and molecular subtypes of PD is of key
importance in order to identify potential dangers and to
develop autophagy-enhancing therapies that target
subtype-specific key pathological processes. The devel-
opment of relevant model systems for these subtypes of
PD is therefore urgently required. Finally, to monitor
therapeutic response of autophagy-enhancing agents, the
development of novel assays that reliably measure dy-
namics in autophagic flux in vivo are highly desired [11].
Conclusion
In conclusion, pioneering studies using macroautophagy-
enhancing agents in preclinical models have provided
important knowledge about the role of autophagy in PD
and highlighted the promising perspective of autophagy
enhancement in this disease. The neuroprotective actions
of broad autophagy enhancement were demonstrated in
various in vivo and in vitro models, with effects on various
modeled neuropathological processes. However, the thera-
peutic potential of macroautophagy-enhancing agents
may be limited due to their lack of selectivity and the
double-edged sword properties of macroautophagy. Re-
cently developed compounds that selectively target down-
stream components of the ALP, including GCase, TFEB
and CMA elements, exert more specific effects on autoph-
agy and may have exciting therapeutic perspective.
Although several fundamental questions need to be fur-
ther addressed before these novel agents can be applied in
a clinical setting, the research field of autophagy is devel-
oping quickly and clinically relevant updates on these
topics may be expected soon. Further characterization of
dysfunctional autophagy in different stages as well as gen-
etic and molecular subtypes of PD in combination with
the effective clinical translation of downstream autophagy
regulation offers exciting new avenues for the develop-
ment of therapeutic strategies in PD.
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